HC Wainwright & Co. analyst Edward White reiterates SAB Biotherapeutics (NASDAQ:SABS) with a Buy, adjusts target to $10 from $1.
HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Adjusts Price Target To $10
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.